Home Cart 0 Sign in  
X

[ CAS No. 1445-69-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1445-69-8
Chemical Structure| 1445-69-8
Chemical Structure| 1445-69-8
Structure of 1445-69-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1445-69-8 ]

Related Doc. of [ 1445-69-8 ]

Alternatived Products of [ 1445-69-8 ]

Product Details of [ 1445-69-8 ]

CAS No. :1445-69-8 MDL No. :MFCD00006888
Formula : C8H6N2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :KGLPWQKSKUVKMJ-UHFFFAOYSA-N
M.W : 162.15 Pubchem ID :219401
Synonyms :

Calculated chemistry of [ 1445-69-8 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 2.0
Molar Refractivity : 45.19
TPSA : 65.72 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.21 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.87
Log Po/w (XLOGP3) : 0.11
Log Po/w (WLOGP) : 0.22
Log Po/w (MLOGP) : 1.41
Log Po/w (SILICOS-IT) : 2.22
Consensus Log Po/w : 0.97

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.53
Solubility : 4.77 mg/ml ; 0.0294 mol/l
Class : Very soluble
Log S (Ali) : -1.05
Solubility : 14.6 mg/ml ; 0.0901 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.13
Solubility : 0.12 mg/ml ; 0.000738 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.88

Safety of [ 1445-69-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1445-69-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1445-69-8 ]
  • Downstream synthetic route of [ 1445-69-8 ]

[ 1445-69-8 ] Synthesis Path-Upstream   1~10

  • 1
  • [ 1445-69-8 ]
  • [ 4752-10-7 ]
YieldReaction ConditionsOperation in experiment
90.1% at 110℃; for 1 h; The compound 1 (1.68 g, 10 mmol) was added to a stirred solution of phosphoruso xychloride (15 ml). The mixture was heated to 110°C for 1 h. After the reaction was complete (monitored by TLC), The reaction mixture was cooled to room temperature. The mixture was added dropwise to crushed ice with stirring for 10 minutes. Then the mixture was filtered through a buchner funnel. the filter cake was washed with H2O until neutral and dried in a vacuum. 2 (1.85 g, 90.1 percent) was obtained as a white solid.
90% at 110℃; for 1 h; The compound 1 (1.68g, 10mmol) was added to a stirred solution of phosphorus oxychloride (15mL). The mixture was heated to 110°C for 1h. After the reaction was complete (monitored by TLC), the reaction mixture was cooled to room temperature. The mixture was added dropwise to crushed ice with stirring for 10min. Then the mixture was filtered through a buchner funnel. The filter cake was washed with H2O until neutral and dried in vacuum. 2 (1.85g, 90percent) was obtained as a white solid. Mp: 192–193°C; 1H NMR (400MHz, DMSO) δ 8.29 (d, J=7.6Hz, 1H, ArH), 8.11–7.94 (m, 3H, ArH)
83.5% for 4 h; Reflux The starting compound 2, 3-dihydrophthalazine-1,4-dione (compound 1) (10.0g, 61.7 mmol) was dissolved in phosphorus oxychloride (45 mL) and stirred under reflux for 4 h. Then most of solvent was removed under vacuum. The residual mixture was poured into ice water (300 ml) and stirred rapidly, and a lot of white solid precipitate out. Then the white solid was collected through filtration and dried in a vacuum to give the compound 2 (10.3 g, 51.5 mmol). M.p. 190-192, yield = 83.5percent. 1H-NMR (CDCl3), δ: 7.93-8.01 (m, 2H, phthalizine-H), 7.60 (d, 2H, J = 7.9 Hz, phthalizine-H).
81% Reflux General procedure: A mixture of phosphorous oxychloride and compound 2 or 4 was heated under reflux overnight. The mixture was cooled to room temperature and excess phosphorous oxychloride was evaporated under reduced pressure. The residue was poured on ice and extracted with DCM. The organic layer was extracted with Na2CO3 solution. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, evaporated under reduced pressure giving compound 3 or 5.
39% With trichlorophosphate In N,N-dimethyl-formamide for 2 h; Heating / reflux A mixture of 2,3-dihydro-ρhthalazine-l,4-dione (185 mg, 1.1 mmol) and DMF (5 drops) in POCl3 (5 mL) was refluxed for 2 h. The solution was then cooled to rt and quenched by careful dropwise addition into ice. The product was then collected via vacuum filtration to provide 88.5 mg (39 percent) of the title compound as a white solid. 1H NMR (DMSO-J6) δ 8.34 - 8.42 (m, 2 H), 8.25 - 8.32 (m, 2 H). HRMS (ES) calcd for C8H5Cl2N2 (M + H) 198.9824, found 198.9832.
22.8% for 2 h; Inert atmosphere; Reflux Phthalhydrazide (1b) (1g, 6.2 mmol), phosphorus oxychloride (2.8 g, 18.6 mmol) and N, N-dimethylformamide were added into a reaction flask successively and refluxed for two hours, and then the reaction solution was carefully and slowly poured into ice water, and then warmed to room temperature, filtrated to remove the solid, the filtrate was concentrated under decreased pressure, and rapid column chromatography was performed with dichloromethane to give 1,4-dichlorophthalazine (2a), 281 mg pale yellow solid (yield 22.8percent).
22.8% With trichlorophosphate In N,N-dimethyl-formamide for 2 h; Reflux Phthalhydrazide (lb) (1 g, 6.2 mmol), phosphorus oxychloride(2.8 g, 18.6 mmol) and N,N-dimethylformamide were added into a reaction flask successively and refluxed for two hours, and then the reaction solution was carefully and slowly poured into ice water, and then warmed to room temperature, filtrated to remove the solid, the filtrate was concentrated under decreased pressure, and rapid column chromatography was performed with dichloromethane to give 1,4- dichlorophthalazine (2a), 281 mg pale yellow solid (yield22.8percent).

Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 4, p. 1236 - 1238
[2] European Journal of Medicinal Chemistry, 2014, vol. 85, p. 235 - 244
[3] Chemical Biology and Drug Design, 2013, vol. 81, # 5, p. 591 - 599
[4] New Journal of Chemistry, 2016, vol. 40, # 7, p. 6070 - 6076
[5] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 6, p. 1576 - 1579
[6] Journal of Natural Products, 2009, vol. 72, # 11, p. 2072 - 2075
[7] European Journal of Medicinal Chemistry, 2010, vol. 45, # 11, p. 4807 - 4812
[8] Asian Journal of Chemistry, 2011, vol. 23, # 1, p. 127 - 131
[9] Organic Process Research and Development, 2011, vol. 15, # 5, p. 1149 - 1162
[10] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 7, p. 2007 - 2013
[11] Journal of Organic Chemistry, 1993, vol. 58, # 4, p. 844 - 849
[12] Patent: WO2006/74223, 2006, A2, . Location in patent: Page/Page column 59
[13] Patent: EP2799435, 2014, A1, . Location in patent: Paragraph 0050; 0072; 0073
[14] Patent: US2015/51211, 2015, A1, . Location in patent: Paragraph 0098; 0099
[15] Journal of the Chemical Society, 1937, p. 16,25
[16] Journal of the Indian Chemical Society, 1990, vol. 67, # 9, p. 779 - 780
[17] Arzneimittel-Forschung/Drug Research, 2010, vol. 60, # 6, p. 289 - 292
[18] Letters in Drug Design and Discovery, 2012, vol. 9, # 4, p. 409 - 414
[19] Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, vol. 28, # 4, p. 792 - 800
[20] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 7, p. 1737 - 1741
[21] Patent: US2015/374705, 2015, A1, . Location in patent: Paragraph 0289; 0290
[22] Patent: CN104016986, 2016, B, . Location in patent: Paragraph 0037
[23] Patent: CN103694244, 2016, B, . Location in patent: Paragraph 0044
[24] Archiv der Pharmazie, 2017, vol. 350, # 12,
  • 2
  • [ 1445-69-8 ]
  • [ 4752-10-7 ]
Reference: [1] Organic and Biomolecular Chemistry, 2012, vol. 10, # 36, p. 7313 - 7320
[2] Australian Journal of Chemistry, 1985, vol. 38, # 11, p. 1685 - 1691
[3] Patent: WO2003/99274, 2003, A1, . Location in patent: Page 277-278
  • 3
  • [ 1445-69-8 ]
  • [ 10025-87-3 ]
  • [ 4752-10-7 ]
Reference: [1] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 541
  • 4
  • [ 1445-69-8 ]
  • [ 19064-73-4 ]
YieldReaction ConditionsOperation in experiment
60%
Stage #1: With phosphorus pentabromide In dichloromethane for 24 h; Heating / reflux
Stage #2: at 120℃; for 2 h;
4-Bromo-2H-phthalazin-1-one: 2,3-Dihydro-1,4-phthalazinedione (12.5 g, 78 mmol) was suspended in DCE (200 ml) and phosphorous pentabromide (50.0 g, 116 mmol) was added in one portion and the reaction heated to reflux for 24 hours. A further portion of phosphorous pentabromide (20.0 g, 70 mol) was added and the reaction heated for a further 24 hours. The reaction was cooled to RT and poured into ice water. The resulting precipitate was filtered and washed with water to give a crude mixture of mono and dibrominated product (22.8 g). This crude material was suspended in HOAc (230.0 mL) and heated to 120° C. for 2 hrs. The reaction was cooled to RT and poured into ice water and the resulting precipitate filtered. The solid was washed with water and dried to give the title compound (10.4 g, 60percent yield) as a white solid. 1H-NMR: (400 MHz, D6-DMSO), 12.95 (1H, s), 8.25 (1H, dd), 8.03 (1H, ddd), 7.96-7.90-(2H, m); MS (ESI+)=(M+H)+ 225 227
Reference: [1] Chemistry - A European Journal, 2016, vol. 22, # 35, p. 12363 - 12370
[2] Patent: US2007/219195, 2007, A1, . Location in patent: Page/Page column 39
[3] Journal of Medicinal Chemistry, 2011, vol. 54, # 1, p. 312 - 319
[4] Patent: US4898872, 1990, A,
[5] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 12, p. 2801 - 2805
[6] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 12, p. 3217 - 3226
  • 5
  • [ 1445-69-8 ]
  • [ 7789-69-7 ]
  • [ 3660-90-0 ]
  • [ 19064-73-4 ]
Reference: [1] Patent: WO2006/32518, 2006, A1, . Location in patent: Page/Page column 154
  • 6
  • [ 1445-69-8 ]
  • [ 3660-90-0 ]
  • [ 19064-73-4 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 135, p. 128,131
[2] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 135, p. 128,131
[3] Journal of Medicinal Chemistry, 2011, vol. 54, # 1, p. 312 - 319
  • 7
  • [ 77959-62-7 ]
  • [ 1445-69-8 ]
  • [ 610-93-5 ]
Reference: [1] Heterocycles, 1982, vol. 18, p. 327 - 341
[2] Heterocycles, 1982, vol. 18, p. 327 - 341
  • 8
  • [ 1445-69-8 ]
  • [ 3682-14-2 ]
Reference: [1] Patent: CN105348202, 2016, A,
  • 9
  • [ 179820-15-6 ]
  • [ 1445-69-8 ]
  • [ 31576-51-9 ]
Reference: [1] Angewandte Chemie - International Edition, 2012, vol. 51, # 5, p. 1152 - 1155
  • 10
  • [ 1445-69-8 ]
  • [ 763114-26-7 ]
Reference: [1] Patent: CN108129397, 2018, A,
Same Skeleton Products
Historical Records